# A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs

> **NCT02510781** · PHASE2 · UNKNOWN · sponsor: **Hospital Affiliated to Military Medical Science, Beijing** · enrollment: 200 (estimated)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Epirubicin
- **DRUG:** Docetaxel
- **DRUG:** Trastuzumab
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT02510781
- **Lead sponsor:** Hospital Affiliated to Military Medical Science, Beijing
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-01
- **Primary completion:** 2016-12
- **Final completion:** 2017-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2015-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02510781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02510781, "A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02510781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*